TheraRadar
← Back
Data updated: May 24, 2026

USPHARMA

Pharma
NeurologyImmunologyGastroenterology

USPHARMA is a pharmaceutical company focused on Neurology, Immunology, Gastroenterology.

1985
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

No active drugs

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

No recent approvals

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Neurology 34%
0 drugs Phase 3: 4 Phase 2: 14 Phase 1: 8
Immunology 23%
0 drugs Phase 3: 5 Phase 2: 6 Phase 1: 2
Gastroenterology 15%
0 drugs Phase 3: 2 Phase 2: 4 Phase 1: 6
Infectious Disease 15%
0 drugs Phase 2: 10 Phase 1: 2
Oncology 14%
0 drugs Phase 3: 1 Phase 2: 2 Phase 1: 13

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

12
Phase 3
36
Phase 2
31
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Neurology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling